Q1 Earnings Forecast for VIR Issued By HC Wainwright

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Vir Biotechnology in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright has a "Buy" rating and a $110.00 price target on the stock. The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.92) per share. HC Wainwright also issued estimates for Vir Biotechnology's Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.77) EPS.

Other research analysts have also issued research reports about the stock. Needham & Company LLC restated a "buy" rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. Barclays lifted their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research note on Thursday, January 9th. Leerink Partners lifted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Finally, Morgan Stanley upgraded Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $35.67.

Remove Ads

Vir Biotechnology Stock Performance

Shares of VIR stock traded down $0.17 on Monday, hitting $8.05. The company had a trading volume of 211,262 shares, compared to its average volume of 2,366,918. Vir Biotechnology has a twelve month low of $6.56 and a twelve month high of $14.45. The firm has a market cap of $1.10 billion, a P/E ratio of -2.05 and a beta of 1.17. The stock's 50-day moving average is $9.50 and its two-hundred day moving average is $8.49.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Vir Biotechnology by 29.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 181,325 shares of the company's stock valued at $1,331,000 after acquiring an additional 40,954 shares during the period. Woodline Partners LP purchased a new stake in Vir Biotechnology in the fourth quarter worth $991,000. Two Sigma Advisers LP increased its position in Vir Biotechnology by 74.8% in the fourth quarter. Two Sigma Advisers LP now owns 74,800 shares of the company's stock worth $549,000 after buying an additional 32,000 shares during the last quarter. Stonepine Capital Management LLC purchased a new position in shares of Vir Biotechnology during the 4th quarter valued at $1,205,000. Finally, Sphera Funds Management LTD. raised its stake in Vir Biotechnology by 523.4% in the 4th quarter. Sphera Funds Management LTD. now owns 581,829 shares of the company's stock valued at $4,271,000 after acquiring an additional 488,500 shares during the period. 65.32% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the company's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares of the company's stock, valued at approximately $16,431,135.32. This represents a 0.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the transaction, the director now directly owns 708,295 shares in the company, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,859 shares of company stock worth $326,458. 15.60% of the stock is owned by corporate insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).